The Big Ten Cancer Research Consortium (BTCRC) arose from the fast-changing personalized medicine environment amid diminishing research opportunities for junior faculty and increasing demands to pre-screen large populations in order to identify small, molecularly-enriched subsets.

The Benefits:

Expedited contracting by virtue of membership

Planned consolidated IRB review

Organized clinical trial working groups

Ability to share specimens with clinically annotated data

Avenue for development of junior faculty

Opportunity to quickly open trials across 11 academic institutions